The Juvenile Diabetes Research Foundation (JDRF) and SmartCells are partnering to advance the company’s SmartInsulin™ product. JDRF will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The collaboration will support milestone-based funding through proof-of-concept clinical trials.
SmartInsulin is being developed as a once-daily, glucose-regulated subcutaneous insulin formulation for treating type 1 diabetes. “Our formulation is designed to address the most critical issue in diabetes treatment—achieving tight glucose control without inducing severe hypoglycemic episodes,” explains Todd C. Zion, Ph.D., president and CEO.
The grant is part of JDRF’s Industry Discovery and Development Partnership Program, which supports companies developing drugs, treatments, and technologies to address type 1 diabetes and its complications. Other companies that have received support from JDRF include EpiVax and Osiris.